Theravance Biopharma, Inc. (TBPH) SVP Buys $105,360.00 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Frank Pasqualone acquired 4,000 shares of the stock in a transaction on Monday, August 21st. The stock was acquired at an average cost of $26.34 per share, for a total transaction of $105,360.00. Following the acquisition, the senior vice president now directly owns 213,180 shares in the company, valued at approximately $5,615,161.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) opened at 28.65 on Friday. Theravance Biopharma, Inc. has a 52 week low of $23.15 and a 52 week high of $43.44. The stock’s 50 day moving average price is $32.26 and its 200 day moving average price is $35.26. The stock’s market cap is $1.54 billion.

WARNING: This news story was published by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at [[permalink]].

Institutional investors have recently made changes to their positions in the company. QS Investors LLC bought a new position in shares of Theravance Biopharma during the second quarter worth $100,000. Ameritas Investment Partners Inc. increased its position in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 3,407 shares in the last quarter. Aperio Group LLC bought a new position in shares of Theravance Biopharma during the second quarter worth $205,000. BNP Paribas Arbitrage SA increased its position in shares of Theravance Biopharma by 570.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 4,383 shares in the last quarter. Finally, Amalgamated Bank bought a new position in shares of Theravance Biopharma during the second quarter worth $214,000. 82.77% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on the company. Evercore ISI assumed coverage on Theravance Biopharma in a report on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price objective on the stock. BidaskClub lowered Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, July 19th. Needham & Company LLC lifted their price objective on Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Finally, Leerink Swann set a $47.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, May 10th. Four research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $41.63.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.